{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:58:04Z","timestamp":1785873484939,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T00:00:00Z","timestamp":1522195200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["14\/177\/09"],"award-info":[{"award-number":["14\/177\/09"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40273-018-0645-2","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T08:18:38Z","timestamp":1522225118000},"page":"1143-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-1990","authenticated-orcid":false,"given":"Rachid","family":"Rafia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Pandor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Harnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Sorour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cutting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,28]]},"reference":[{"key":"645_CR1","unstructured":"National Institute for Health and Care Excellence, Guide to the methods of technology appraisal. London UK, 2013: Available at: https:\/\/www.nice.org.uk\/article\/pmg9\/ [Last accessed 07 March 2018]."},{"key":"645_CR2","unstructured":"Rafia R, P.A., Stevens J, Harnan S, Davis S, Clowes M, McMillan A, Sorour Y, Cutting R, Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma: a single technology appraisal. School of Health and Related Research (ScHARR), 2016: Available at: https:\/\/www.nice.org.uk\/guidance\/ta472\/documents\/appraisal-consultation-document-2 [Last acessed 07 March 2018]."},{"key":"645_CR3","unstructured":"National Institute for Health and Care Excellence, Final appraisal determination: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab. London UK, 2016: Available at: https:\/\/www.nice.org.uk\/guidance\/ta472\/documents\/final-appraisal-determination-document [Last accessed 07 March 2018]."},{"key":"645_CR4","unstructured":"National Institute for Health and Care Excellence, Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab; Technology appraisal guidance [TA472]. London UK, 2017: Available at: https:\/\/www.nice.org.uk\/guidance\/ta472\/history [Last accessed 07 March 2018]."},{"key":"645_CR5","unstructured":"National Institute for Health and Care Excellence, Non-Hodgkin\u2019s lymphoma: diagnosis and management: NICE guideline [NG52]. London UK, 2016: Available at: https:\/\/www.nice.org.uk\/guidance\/ng52 [Last accessed 07 March 2018]."},{"key":"645_CR6","unstructured":"Roche Products Limited, Gazyvaro\u25bc (obinutuzumab) in combination with bendamustine for treating rituximab-refractory follicular lymphoma. Company evidence submission to NICE, 2016: Available at: https:\/\/www.nice.org.uk\/guidance\/ta472\/documents\/appraisal-consultation-document-2 [Last acessed 07 March 2018]."},{"key":"645_CR7","unstructured":"Roche Products Limited, ID841 Gazyvaro (obinutuzumab) with bendamustine for treating follicular lymphoma refractory to rituximab - Response to ACD. 2016, National Institute for Health and Care Excellence: London UK. Available at: https:\/\/www.nice.org.uk\/guidance\/ta472\/documents\/appraisal-consultation-document-2 [Last acessed 07 March 2018]."},{"key":"645_CR8","unstructured":"Roche Products Ltd, Gazyvaro\u25bc (obinutuzumab) in combination with bendamustine for treating rituximab-refractory follicular lymphoma: Response to clarification. 2016: Available at: https:\/\/www.nice.org.uk\/guidance\/ta472\/documents\/appraisal-consultation-document-2 [Last acessed 07 March 2018]."},{"key":"645_CR9","unstructured":"Cheson B. et al. GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. In: 13th International Conference on Malignant Lymphoma, 2015: Abstract 123."},{"key":"645_CR10","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1200\/jco.2015.33.18_suppl.lba8502","volume":"33","author":"L Sehn","year":"2015","unstructured":"Sehn L, et al. GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2015;33:8502 (ASCO Annual Meeting).","journal-title":"J Clin Oncol"},{"key":"645_CR11","doi-asserted-by":"crossref","unstructured":"Pott C. et al. Analysis of minimal residual disease in follicular lymphoma patients in GADOLIN, a Phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed\/refractory indolent non-Hodgkin lymphoma. In: ASH 57th Annual Meeting and Exposition. 2015: Orlando, Florida. Abstract 3978","DOI":"10.1182\/blood.V126.23.3978.3978"},{"key":"645_CR12","doi-asserted-by":"crossref","unstructured":"Cheson B et al Primary results of the health-related quality of life assessment from the Phase III GADOLIN study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory, indolent non-Hodgkin lymphoma. In: ASH 57th Annual Meeting and Exposition. 2015: Orlando, Florida. Abstract 1523.","DOI":"10.1182\/blood.V126.23.1532.1532"},{"key":"645_CR13","unstructured":"F. Hoffmann-La Roche Ltd, Primary Clinical Study Report\u2014GAO4753g\/GO01297\u2014An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine\u2009+\u2009RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin\u2019s lymphoma. Clinical Study Report\u20141051204. July 2015."},{"key":"645_CR14","unstructured":"F. Hoffmann-La Roche Ltd, Update Clinical Study Report\u2014GAO4753g\/GO01297\u2014An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine\u2009+\u2009RO5072759 (GA101) in patients with rituximabrefractory, indolent non-Hodgkin lymphoma. Report No. 1067639. December 2015."},{"key":"645_CR15","unstructured":"National Institute for Health and Care Excellence, Final Scope: Obinutuzumab in combination with bendamustine for treating rituximabrefractory follicular lymphoma. London, UK, 2016: Avaialble at: https:\/\/www.nice.org.uk\/guidance\/ta472\/documents\/final-scope [Last accessed 07 March 2018]."},{"key":"645_CR16","unstructured":"Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. US: Wiley; 2011. http:\/\/handbook.cochrane.org ."},{"issue":"5","key":"645_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","volume":"273","author":"KF Schulz","year":"1995","unstructured":"Schulz KF, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408\u201312.","journal-title":"JAMA"},{"key":"645_CR18","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1001\/jama.282.11.1054","volume":"282","author":"P Juni","year":"1999","unstructured":"Juni P, et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054\u201360.","journal-title":"JAMA"},{"issue":"33","key":"645_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta5330","volume":"5","author":"S Brookes","year":"2001","unstructured":"Brookes S, et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5(33):1\u201356.","journal-title":"Health Technol Assess"},{"key":"645_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30157-7","author":"PA Hamlin","year":"2016","unstructured":"Hamlin PA. Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma. Lancet Oncol. 2016. https:\/\/doi.org\/10.1016\/S1470-2045(16)30157-7 .","journal-title":"Lancet Oncol"},{"issue":"6","key":"645_CR21","doi-asserted-by":"publisher","first-page":"A294","DOI":"10.1016\/S1098-3015(10)63491-2","volume":"9","author":"D Wild","year":"2006","unstructured":"Wild D, Pettengell R, Walker M, et al. Utility elicitation in patients with follicular lymphoma. Value Health. 2006;9(6):A294.","journal-title":"Value Health"},{"key":"645_CR22","doi-asserted-by":"crossref","unstructured":"Papaioannou D, Rafia R, Rathbone J, Stevenson M, Woods HB, Stevens J. Rituximab for the first-line treatment of stage III\u2013IV follicular lymphoma (review of technology appraisal no. 110): a systematic review and economic evaluation. Health Technol Assess. 2012;16(37):1\u2013253, iii\u2013iv.","DOI":"10.3310\/hta16370"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0645-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0645-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0645-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T12:20:29Z","timestamp":1570969229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0645-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,28]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0645-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,28]]},"assertion":[{"value":"28 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number 14\/177\/09 STA). See the HTA programme website for further project information ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RR, AP, SD, JWS, SH, MC, YS and RC have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}